Investigators at Yale University Detail Findings in Cancer (When Covering and Discovering Are At Odds: How the Logic of Us Health Insurance Undercuts the Promise and Equity of Precision Medicine for People With Hereditary Cancer Risks): Cancer

2026 AUG 17 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News -- Fresh data on Cancer are presented in a new report. According to news reporting out of New Haven, Connecticut, by NewsRx editors, research stated, “Despite precision medicine’s promise to revolutionize health care, access remains uneven, and disparities persist. This study examines how conflicts between the institutional logics of genetic science (‘discovering’) and market-based health insurance (‘covering’) impede precision-driven health equity.”

Financial support for this research came from NIH National Human Genome Research Institute (NHGRI).

Our news journalists obtained a quote from the research from Yale University, “The authors conducted 44 semistructured in-depth interviews with individuals at elevated risk for hereditary cancer. Data were analyzed using an abductive approach, combining thematic analysis with grounded theory tools. Analysis reveals seven ‘zones of conflict’ where precision medicine’s aspirations clash with insurance practices, creating barriers to genetic testing and related services. These zones span initial access barriers (e.g., complex billing, inconsistent guideline uptake) and downstream care factors (e.g., financial concerns, lack of retesting guidelines). The interplay between expanding genomic knowledge and the fragmented American health care system particularly disadvantages underrepresented and minority populations. Participant experiences reveal more unanticipated sources of inequity than precision medicine proponents anticipated. Incremental reforms targeting these conflict zones-such as guideline harmonization, expanding coverage mandates, and enhancing patient advocacy related to insurance coverage-could mitigate cascading disparities.”

According to the news editors, the research concluded: “This study highlights the importance of addressing institutional misalignments to realize the full equitable potential of precision medicine involving genetics.”

This research has been peer-reviewed.

For more information on this research see: When Covering and Discovering Are At Odds: How the Logic of Us Health Insurance Undercuts the Promise and Equity of Precision Medicine for People With Hereditary Cancer Risks. Journal of Health Politics, Policy and Law, 2026;51(3):433-467. Journal of Health Politics, Policy and Law can be contacted at: Duke Univ Press, 905 W Main St, Ste 18-B, Durham, NC 27701, USA.

Our news journalists report that additional information may be obtained by contacting Mark Schlesinger, Yale University, Inst Social & Policy Studies, New Haven, CT 06520, United States. Additional authors for this research include Emily Hammad Mrig, Jennifer M. Weiss, Nancy Pandhi, Katherine Clegg Smith, Nora Jacobson and Rachel Grob.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1215/03616878-12317993. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)